NCT01656343View on ClinicalTrials.gov

Belatacept and Risk of Post-transplant Lymphoproliferative Disorder in US Renal Transplant Recipients

CompletedOBSERVATIONAL
Enrollment

775

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

August 5, 2019

Study Completion Date

August 5, 2019

Conditions
Kidney TransplantationTransplantation, Kidney
Interventions
DRUG

Calcineurin inhibitors (CNI)

No Intervention

DRUG

Belatacept

No Intervention

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT01656343 - Belatacept and Risk of Post-transplant Lymphoproliferative Disorder in US Renal Transplant Recipients | Biotech Hunter | Biotech Hunter